Patent Number: 7,820,160

Title: Midkine inhibitory compositions for the treatment of angiostenosis

Abstract: The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.

Inventors: Kadomatsu; Kenji (Aichi, JP), Horiba; Mitsuru (Aichi, JP), Muramatsu; Takashi (Aichi, JP), Ikematsu; Shinya (Kanagawa, JP), Sakuma; Sadatoshi (Kanagawa, JP)

Assignee: Medical Therapies Limited

International Classification: A61K 39/395 (20060101); A61K 48/00 (20060101)

Expiration Date: 2018-10-26 0:00:00